Original papers in peer-reviewed journals:
- Pozo-Rosich P (CA), van Veelen N, Caronna E, Vaghi G, Torres-Ferrus M, van der Arend BWH, Goadsby PJ, Ashina M, Wang SJ, Diener HC, Tassorelli C, Terwindt GM. Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache. Cephalalgia 2025;45:3331024251318016
doi: 10.1177/03331024251318016. PMID 40095946
Impact factor: 5.000
- Sacco S, Ashina M, Diener HC, Haghdoost F, Lee MJ, Monteith TS, Jenkins B, Peres MFP, Pozo-Rosich P, Ornello R, Puledda F, Sakai F, Schwedt TJ, Terwindt G, Vaghi G, Wang SJ, Ahmed F, Tassorelli C. Setting higher standards for migraine prevention: A position statement of the International Headache Society. Cephalalgia 2025;45:333102451320608
doi: 10.1177/03331024251320608. PMID 39980456
Impact factor: 5.000
- Gine-Cipres E, Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Pozo-Rosich P (CA). Quality of Headache Management in Inpatients. Pain Management Nursing 2025:S1524-9042(24)00317-5
doi: 10.1016/j.pmn.2024.12.006. PMID 39799047
- Pozo-Rosich P (CA). Headache research in 2024: new data on migraine prevention. Lancet Neurol 2025;24:11-13
doi: 10.1016/S1474-4422(24)00485-X. PMID 39706618
Impact factor: 46.600
- Gottschalk C, Gandhi P, Pozo-Rosich P, Christie S, Tassorelli C, Stokes J, Liu Y, Luo L, Nagy K, Trugman JM, Lipton RB. Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials. Cephalalgia 2024;44:3331024241300305
doi: 10.1177/03331024241300305. PMID 39648617
Impact factor: 5.000
- Pozo-Rosich P, García-Azorín D. Díaz-Cerezo S, Fernandez-Montoya J, de Paz HD, Nuñez M. Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review. Front Neurol 2024;15:1502575. eCollection 2024
doi: 10.3389/fneur.2024.1502475. PMID 39639987
Impact factor: 2.700
- Rosignoli C, Ornello R, Caponnetto V, Onofri A, Avaltroni S, Braschinsky M, Sved O, Gil-Gouveia R, Lampl C, Paungarttner J, Martelletti P, Wells-Gatnik WD, Martins IP, Mitsikostas D, Apostolakopoulou L, Nabaei G, Izge A, Narin DB, Pozo-Rosich P, Muñoz-Vendrell A, Prudenzano MP, Gentile M, Ryliskiene K, Vainaskiene J, Del Rio MS, Vernieri F, Iaccarino G, Waliszewka-Prosol M, Budrewicz S, Carnovali M, Katsarava Z, Sacco S. Resistant and refractory migraine – two different entities with different comorbidities? Results from the REFINE study. Journal Headache Pain 2024;25:212
doi: 10.1186/s10194-024-01910-3. PMID 39627727
Impact factor: 7.300
- Ailani J, Lalla A, Halker Singh RB, Holle-Lee D, Nagy K, Kelton K, Piron C, Gandhi P, Pozo-Rosich P. Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies. Cephalalgia 2024;44:333102424199377
doi: 10.1177/03331024241299377. PMID 39558612
Impact factor: 5.000
- Gonzalez-Martinez A, Ray JC, Haghdoost F, Ashraf U, Cerrahoglu ST, Dantes MC, Gosalia H, Hwang H, Kim JM, Lange KS, Jennysdotter Olofsgard F, Caronna E, Pozo-Rosich P (CA); International Headache Academy of the International Headache Society. Time and headache: Insights into timing processes in primary headache disorders for diagnosis, underlying pathophysiology and treatment implications. Cephalalgia 2024;44:3331024241297652
doi: 10.1177/03331024241297652. PMID 39558611
Impact factor: 5.000
- Cammarota F, De Icco R, Vaghi G, Corrado M, Bighiani F, Martinelli D, Pozo-Rosich P, Goadsby PJ, Tassorelli C. High-frequency episodic migraine: Time for its recognition as a migraine subtype? Cephalalgia 2024;44:3331024241291578
doi: 10.1177/03331024241291578. PMID 39434667
Impact factor: 5.000
- Sebastianelli G, Çimen Atalar A, Cetta I, Farham F, Fitzek M, Karatas-Kursun H, Kholodova M, Kukumägi K-H, Montisano DA, Onan D, Pantovic A, Skarlet J, Sotnikov D, Caronna E, Pozo-Rosich P (CA); International Headache Academy of the International Headache Society (IHS-iHEAD). Insights from triggers and prodromal symptoms on how migraine attacks start. The threshold hypothesis. Cephalalgia 2024;44:33331024241287224
doi: 10.1177/03331024241287224. PMID 39380339
Impact factor: 5.000
- Elosua-Bayes I, Alpuente A, Melgarejo L, Caronna E, Torres-Ferrus M, Pozo-Rosich P (CA). Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: enhancing safety data. Cephalalgia 2024;44:3331024241273966.
doi: 10.1177/03331024241273966. PMID 39314064
Impact factor: 5.000
- Membrilla JA, Alpuente A, Gomez-Dabo L, Garcia-Yu R, Mariño E, Diaz de Teran J, Pozo-Rosich P (CA). Code Headache: development of a protocol for optimizing headache management in the emergency room. Eur J Neurol 2024;31(12):e16484
doi: 10.1111/ene.16484. PMID 39287050
Impact factor: 4.500
- Ihara K, Casillo F, Dahshan A, Genç H, Jusupova A, Karbozova K, Lee W, Chia Law Yi, Mavridis T, Park HK, Polat B, Unt TH, Vashchenko N, Zhantleuova A, Pozo-Rosich P, Schwedt TJ. Are we closer to achieving precision medicine for migraine treatment? A narrative review. Cephalalgia 2023;44:3331024241281518
doi 10.1177/03331024241281518. PMID 39256924
Impact factor: 5.000
- Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S, Burstein R, Liebler E, Cipriani A, Chu MK, Cocores A, Dodd-Glover F, Ekizoglu E, Garcia-Azorin D, Göbel C, Goicochea MT, Hassan A, Hirata K, Hoffmann J, Jenkins B, Kamm K, Lee MJ, Ling YH, Lisicki M, Martinelli D, Monteith TS, Ornello R, Ozge A, Peres M, Pozo-Rosich P, Romanenko V, Schwedt TJ, Souza MNP, Takizawa T, Terwindt GM, Thuraiaiyah J, Togha M, Vandenbussche N, Wang SJ, Yu S, Tassorelli C. International Headache Society global practice recommendations for the preventive pharmacological treatment of migraine. Cephalalgia 2024;44:3331024241269735.
doi: 10.1177/03331024241269735. PMID 39262214
Impact factor: 5.000
- Peres MFP, Sacco S, Pozo-Rosich P, Tassorelli C, Ahmed F, Burstein R, Ashina S, Uluduz D, Husoy AK, Steiner TJ. Migraine is the most disabling neurological disease among children and adolescents, and second after stroke among adults: a call to action. Cephalalgia 2024;44:3331024241267309
doi 10.1177/03331024241267309. PMID 39197864
Impact factor: 5.000
- Pozo-Rosich P (CA), Alpuente A, Silberstein SD, Burstein R. Insights from 25 years of onabotulinumtoxinA in migraine – mechanisms and management. Nat Rev Neurol 2024;20:555-568
doi: 10.1038/s41582-024-01002-5. PMID 39160284
Impact factor: 28.200
- Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S, Burstein R, Liebler E, Cipriani A, Chu MK, Cocores A, Dodd-Glover F, Ekizoglu E, Garcia-Azorin D, Göbel C, Goicochea MT, Hassan A, Hirata K, Hoffmann J, Jenkins B, Kamm K, Lee MJ, Ling YH, Lisicki M, Martinelli D, Monteith TS, Ornello R, Ozge A, Peres M, Pozo-Rosich P, Romanenko V, Schwedt TJ, Souza MNP, Takizawa T, Terwindt GM, Thuraiaiyah J, Togha M, Vandenbussche N, Wang SJ, Yu S, Tassorelli C. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 2024;44:3331024241252666
doi:10.1177/03331024241252666. PMID 39133176
Impact factor: 5.000
- Schwedt TJ, Pradhan AA, Oshinsky ML, Brin MF, Rosen H, Lalvani N, Charles A, Ashina M, Phu Do T, Burstein R, Gelfand AA, Dodick DW, Pozo-Rosich P, Lipton RB, Ailani J, Szperka CL, Charleston IV L, Digre KB, Russo AF, Buse DC, Powers SW, Tassorelli C, Goadsby PJ, on behalf of the Headache Research Priorities Working Group Members. The headache research priorities: Research goals from the American Headache Society and an international multistakeholder expert group. Headache 2024;64:912-930
doi: 10.1111/head.14797. PMID 39149968
Impact factor: 5.400
- Navarro-Perez MP, González-Quintanilla V, Muñoz-Vendrell A, Madrigal E, Alpuente A, Latorre G, Molina F, Monzon MJ, Medrano V, Garcia-Azorin D, Gonzalez-Oria C, Gago-Veiga A, Velasco F, Beltran I, Morollon N, Viguera J, Casas-Limon J, Rodriguez-Vico J, Cuadrado E, Irimia P, Iglesias F, Guerrero-Peral A, Belvis R, Pozo-Rosich P, Pascual J, Santos S. Long-term safety of onabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study. Front Neurol 2024;15:1417831
doi: 10.3389/fneur.2024.1417831. PMID 38938776
Impact factor: 2.700
- Qu K, Li MX, Yu P; International Headache Genetics Consortium; Wu BH, Shi M, Dong M. HMG-CoA reductase is a potential therapeutic target for migraine: a mendelian randomization study. Sci Rep 2024;14:12094
doi: 10.1038/s41598-024-61628-9. PMID 38802400
Impact factor: 3.800
- Gomez-Dabó L, Caronna E, Mas-de-les-Valls R, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). Effectiveness and safety of onabotulinumtoxinA in adolescent patients with chronic migraine. Toxins (Basel) 2024;16:221
doi: 10.3390/toxins16050221. PMID 38787073
Impact factor: 3.900
- Caronna E, Gallardo VJ, Egeo G, Vázquez MM, Castellanos CN, Membrilla JA, Vaghi G, Rodríguez-Montolio J, Fabregat Fabra N, Sánchez-Caballero F, Jaimes Sánchez A, Muñoz-Vendrell A, Oliveira R, Gárate G, González-Osorio Y, Guisado-Alonso D, Ornello R, Thunstedt C, Fernández-Lázaro I, Torres-Ferrús M, Alpuente A, Torelli P, Aurilia C, Pére RL, Castrillo MJR, Icco R, Sances G, Broadhurst S, Ong HC, García AG, Campoy S, Sanahuja J, Cabral G, Beltrán Blasco I, Waliszewska-Prosół M, Pereira L, Layos-Romero A, Luzeiro I, Dorado L, Álvarez Escudero MR, May A, López-Bravo A, Martins IP, Sundal C, Irimia P, Lozano Ros A, Gago-Veiga AB, Juanes FV, Ruscheweyh R, Sacco S, Cuadrado-Godia E, García-Azorín D, Pascual J, Gil-Gouveia R, Huerta-Villanueva M, Rodriguez-Vico J, Viguera Romero J, Obach V, Santos-Lasaosa S, Ghadiri-Sani M, Tassorelli C, Díaz-de-Terán J, Díaz Insa S, Oria CG, Barbanti P, Pozo-Rosich P (CA); EUREkA study group. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry 2024;95:927-937
doi: 10.1136/jnnp-2023-333295. PMID 38777579
Impact factor: 8.800
- Li G, Duan S; International Headache Genetics Consortium, (IHGC), Zheng T, Zhu T, Qu B, Liu L, Liu Z. Genetic causal relationship between immune diseases and migraine: a Mendelian randomization study. Front Immunol 2024;15:1376698
doi: 10.3389/fimmu.2024.1376698. PMID 38650934
Impact factor: 5.700
- Lipton RB, Nahas SJ, Pozo-Rosich P, Bilchik T, Mc Allister P, Finnegan M, Liu Y, Chalermpalanupap N, Dabruzzo B, Dodick DW. Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial. Journal Headache Pain 2024;25:83
doi: 10.1186/s10194-024-01783-6. PMID 38773375
Impact factor: 7.300
- Belvis R, Irimia P, Gonzalez N, García-Ull J, Pozo-Rosich P, Lopez-Bravo A, Morollon N, Quintas S, Plana A, Baz PG, Tentor A, Gallego Artiles N, Leon FJ, Perez Martin M, Rivera I, Ramirez R, Colomina I, Lainez JM, Pascual J. Migraine treatment consensus of the Spanish Society of Neurology (SEN), Spanish Society of Family and Community Medicine (SEMFYC), Society of Primary Care Medicine (SEMERGEN) and Spanish Association of Migraine and Headache (AEMICE) on migraine treatment. Med Clin (Barc). 2024;S0025-7753(24)00137-4.
doi: 10.1016/j.medcli.2024.02.006. PMID: 38643025
Impact factor: 2.600
- Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P (CA). Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterization. Journal Headache Pain 2024;25:58.
doi: 10.1186/s10194-024-01772-9. PMID: 38637736
Impact factor: 7.300
- Mitsikostas DD, Caronna E, De Tommaso M, Deligianni CI, Ekizoglu E, Bolay H, Göbel CH, Kristoffersen ES, Lampl C, Moro E, Pozo-Rosich P, Sellner J, Terwindt G, Irimia-Sieira P. Reply to the letter: Headaches during/after SARS-CoV-2 infection/vaccination can be primary and secondary as well as acute and chronic, by Finsterer J and Mehri S. Eur J Neurol 2024:e16308
doi: 10.1111/ene.16308. PMID: 38628031
Impact factor: 4.500
- Alpuente A, Torres-Ferrus M, Caronna E, Pozo-Rosich P (CA). The state of the art on the use of patient reported outcomes in migraine. Curr Opin Neurol 2024;37:271-282
doi: 10.1097/WCO.0000000000001267. PMID: 38529698
Impact factor: 4.100
- Pozo-Rosich P, Carmo M, Muñiz A, Armada B, Moya-Alarcón C, Pascual J. Migraine treatment: quo vadis? Real-word data study (2015-2022) in Spain. BMC Neurol 2024;24:107
doi: 10.1186/s12883-024-03600-8. PMID: 38566063
Impact factor: 2.200
- Pozo-Rosich P (CA), Dolezil D, Paemelaire K, Stephen A, Stude P, Snellman J, Arkuszewski M, Stites T, Ritter S, Lopez Lopez C, Maca J, Ferraris M, Gil-Gouveia R. Early use of erenumab vs nonspecific oral migraine preventives. The APPRAISE randomized clinical trial. JAMA Neurology 2024:81(5):461-470
doi: 10.1001/jamaneurol.2024.0368. PMID: 38526461
Impact factor: 20.900
- Irimia P, Santos-Lasaosa S, Pozo-Rosich P, Leira R, Pascual J, Lainez JM. Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review. Front Neurol 2024;15:1355877
doi: 10.3389/fneur.2024.1355877. eCollection 2024.PMID: 38523607
Impact factor: 2.700
- Ashina H, Diener HC, Tassorelli C, Scher AI, Lipton RB, Pozo-Rosich P, Sinclair AJ, Chong CD, Finkel AD, Ashina M, Schwedt TJ, Dodick DW, Terwindt GM. Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury. Cephalalgia 2024;44:3331024241234068.
doi: 10.1177/03331024241234068. PMID: 38518177
Impact factor: 5.000
- Pozo-Rosich P (CA), Poveda JL, Crespo C, Martinez A, Rodriguez JM, Irimia P. Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis. Journal Headache Pain 2024;25:40
doi: 10.1186/s10194-024-01747-w.PMID: 38491460
Impact factor: 7.300
- Ikumi N, Marti-Marca A, Torre-Suñe A, Cerda-Company X, Vila-Ballo A, Gallardo VJ, Caronna E, Alpuente A, Pozo-Rosich P. Quantifying sensory thresholds along the migraine cycle. Quantifying sensory thresholds along the migraine cycle: an exploratory longitudinal study. Cephalalgia 2024;3331024241230279
doi: 10.1177/03331024241230279.PMID: 38416486
Impact factor: 5.000
- Mitsikostas DD, Caronna E, de Tomasso M, Deligianni CI, Ekizoglu E, Bolay H, Göbel CH, Kristoffersen ES, Lampl C, Moro E, Pozo-Rosich P, Sellner J, Terwindt G, Irimia P. Headaches and facial pain attributed to SARS-CoV-2 infection and vaccination: a systematic review. European Journal Neurology 2024;00:e16251.
doi 10.1111/ene.16251. PMID: 38415282
Impact factor: 4.500
- Goadsby PJ, Evers S, Gelfand AA, Lipton RB, May A, Pozo-Rosich P, Schoenen J, Schwedt TJ, Tassorelli C, Terwindt G, Wang SJ. International Classification of Headache Disorders-4 – Work in progress 1. Cephalalgia 2024 44(2):3331024241233937
doi: 10.1177/03331024241233937.PMID: 38388354
Impact factor: 5.000
- Tassorelli C, Nagy K, Pozo-Rosich P, Lanteri-Minet M, Sacco S, Nezádal T, Guo H, De Abreu Ferreira R, Forero G, Trugman JM. Safety and efficacy for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol 2024;S1474-4422(24)00025-5
doi: 10.1016/S1474-4422(24)00025-5. Epub 2024 Feb 13.PMID: 38364831
Impact factor: 46.500
- Lazaro-Hernandez C, Caronna E, Rosell-Mirmi J, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population. Journal Headache Pain 2024;25:21
doi: 10.1186/s10194-024-01727-0.PMID: 38347485
Impact factor: 7.300
- Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). CGRP monoclonal antibodies and CGRP receptor antagonists (gepants) in migraine prevention. Handbook Clinical Neurology 2024;199:107-124
doi: 10.1016/B978-0-12-823357-3.00024-0.PMID: 38307640
- Torres- Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (CA). Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies. Cephalalgia 2024;44:3331024231222923
doi: 10.1177/03331024231222923.PMID: 38307497
Impact factor: 5.000
- Pozo-Rosich P (CA), Ashina M, Tepper SJ, Jensen S, Boserup LP, Josiassen MK, Sperling B. Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study. Neurol Ther. 2024;13:339-353.
doi: 10.1007/s40120-023-00575-5. PMID: 38236314.
Impact factor: 4.000
- Yu S, Zhou J, Luo G, Xiao Z, Ettrup A, Jansson G, Florea I, Ranc K, Pozo-Rosich P. Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study. BMC Neurol 2023;23:441
doi: 10.1186/s12883-023-03477-z.PMID: 38102535
Impact factor: 2.200
- Ashina M, Mitsikostas DD, Amin FM, Koturk P, Schankin CJ, Sahin G, Pozo-Rosich P, Dorman PJ, Nezadal T, Poole AC, Martins IP, Sumelahti ML, Ramirez Campos V, Ahn AH, Lyras L, Tassorelli C. Real-world effectiveness of fremanezumab for the preventive treatment of migraine: interim analysis of the pan-European, prospective, observational, phase 4 PEARL study. Cephalalgia 2023;43:3331024231214987
doi: 10.1177/03331024231214987.PMID: 37987641
Impact factor: 5.000
- Lipton RB, Pozo-Rosich P, Orr SL, Reed ML, Fanning KM, Dabruzzo B, Buse DC. Impact of monthly headache days on migraine-related quality of life: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache 2023
doi: 10.1111/head.14629. Epub 2023 Oct 5.PMID: 37795746
Impact factor: 5.400
- Melgarejo L, Caronna E, Rosell-Mirmi J, Elosua-Bayés I, Alpuente A, Torres-Ferrus M, Gallardo VJ, Pozo-Rosich P (CA). Migraine worsening after COVID-19 and COVID-19 vaccination: are we facing a nocebo effect? Eur J Neurol 2023
doi: 10.1111/ene.16058. Epub 2023 Oct 4.PMID: 37791410
Impact factor: 4.500
- Kim SA, Choi SY, Youn MS, Pozo-Rosich P, Lee MJ. Epidemiology, burden and clinical spectrum of cluster headache: a global update. Cephalalgia 2023;43:
doi: 10.1177/03331024231201577.PMID: 37728577
Impact factor: 5.000
- Labastida-Ramirez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D, Naghshineh H, Meksa L, Chkhitnidze N. Gudadze T, Pozo-Rosich P, Burstein R, Hoffmann J. Mode and site of action of therapies targeting CGRP signaling. Journal Headache Pain 2023;24:125
doi: 10.1186/s10194-023-01644-8.PMID: 37691118
Impact factor: 7.300
- Gomez-Dabo L, Melgarejo-Martinez L, Caronna E, Pozo-Rosich P (CA). Headache in COVID-19 and long COVID: to know facts for clinical practice. Curr Neurol Neurosci Rep 2023 Oct;23(10):551-560.
doi: 10.1007/s11910-023-01296-w. Epub 2023 Sep 4.PMID: 37665495
Impact factor: 4.800
- Molan SP, Fraser CL, Digre KB, Diener HC, Lipton RB, Juhler M, Miller NR, Pozo-Rosich P, Togha M, Brock K, Dinkin MJ, Chan CKM, Tassorelli C, Sinclair AJ, Terwindt GM, Jensen RH. Guidelines of the International Headache Society for Controlled Clinical Trials in Idiopathic Intracranial Hypertension. Cephalalgia 2023;43:3331024231197118
doi: 10.1177/03331024231197118.PMID: 37661711
Impact factor: 5.000
- De Boer I, Ambrosini A, Halker Singh RB, Baykan B, Buse DC, Tassorelli C, Jensen RH, Pozo-Rosich P, Terwindt GM; International Headache Society Women’s Leadership Forum. Harassment in the headache field: a global web-based cross-sectional survey. Cephalalgia 2023;43(8)
doi: 10.1177/03331024231193099.PMID: 37652444
Impact factor: 5.000
- Buse DC, Pozo-Rosich P, Dupont-Benjamin L, Balkaran BL, Lee L, Jauregui A, Gandhi P, Parikh M, Reuter U. Impact of headache frequency and preventive medication failure on quality of life, functioning, and costs among individuals with migraine across several European countries: need for effective preventive treatment. Journal Headache Pain 2023;24:115
doi: 10.1186/s10194-023-01655-5.PMID: 37612633
Impact factor: 7.300
- Gonzalez R, Aymerich FX, Alberich M, Caronna E, Gallardo VJ, Pozo-Rosich P, Rovira A, Pareto D. Estimation of the density of veins from susceptibility-weighted imaging by using the Mamdani fuzzy-type rule-based system. Investigating the neurovascular coupling in migraine. Neuroimage Clin 2023;39:103489
doi: 10.1016/j.nicl.2023.103489. PMID: 37611372
Impact factor: 3.400
- Alpuente A, Torre-Sune A, Caronna E, Gine-Cipres E, Torres-Ferrus M, Pozo-Rosich P (CA). Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: a real-world evidence study. Cephalalgia 2023;43:3331024231177636
doi: 10.1177/03331024231177636.PMID: 37555331
Impact factor: 5.000
- Vila-Pueyo M, Gliga O, Gallardo VJ, Pozo-Rosich P. The role of glial cells in different phases of migraine: lessons from preclinical studies. International Journal of Molecular Sciences 2023;24:12553
doi: 10.3390/ijms241612553.PMID: 37628733
Impact factor: 4.900
- Marti-Marca A, Vila-Ballo A, Cerda-Company X, Ikumi N, Torres-Ferus M, Caronna E, Gallardo VJ, Alpuente A, Torralba Cuello M, Soto-Faraco S, Pozo-Rosich P (CA). Exploring sensory sensitivity, cortical excitability, and habituation in episodic migraine, as a function of age and disease severity, using pattern-reversal task. The Journal of Headache and Pain 2023;24:104
doi: 10.1186/s10194-023-01618-w.PMID: 37545005
Impact factor: 7.300
- Pozo-Rosich P (CA), Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, Guo H, Schwefel B, Lu K, Boinpally R, Miceli R, De Abreu Ferreira R, McCusker E, Yu SY, Severt L, Finnegan M, Trugman JM. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023:S0140-6736(23)01049-8
doi: 10.1016/S0140-6736(23)01049-8. Epub 2023 Jul 26.PMID: 37516125
Impact factor: 98.400
- May A, Evers S, Goadsby PJ, Leone M, Manzoni GC, Pascual J, Carvalho V, Romoli M, Aleksovska K, Pozo-Rosich P, Jensen RH, European Academy of Neurology Task Force. European Academy of Neurology Guidelines on the treatment of cluster headache. Eur J Neurol 2023.
doi: 10.1111/ene.15956. Epub 2023 Jul 28.PMID: 37515405
Impact factor: 4.500
- Winsvold BS, Harder AVE, Ran C, Chalmer MA, Dalmasso MC, Ferkingstad E, et al. Cluster headache genome-wide association study and meta-analysis identifies eight loci and implicates smoking as a causal risk factor. Ann Neurol 2023;94:713-726
doi: 10.1002/ana.26743. Epub 2023 Aug 7.PMID: 37486023
Impact factor: 8.100
- He Q, Wang W, Xiong Y, Tao C, Ma L, Ma J, You C, International Headache Genetics Consortium. A causal effect of gut microbiota in the development of migraine. J Headache Pain 2023;24:90.
doi: 10.1186/s10194-023-01609-x.PMID: 37460956
Impact factor: 7.300
- Mitsikostas DD, Waeber C, Sanchez-del-Rio M, Raffaelli B, Ashina H, Maassen van den Brink A, Andreou A, Pozo-Rosich P. Rapoport A, Ashina M, Moskowitz MA. The 5-HT1F receptor as the target of ditans in migraine – from bench to bedside. Nat Rev Neurol 2023;19:489-505
doi: 10.1038/s41582-023-00842-x. Epub 2023 Jul 12.PMID: 37438431
Impact factor: 28.200
- Zhang W, Zhang L, Yang L, Xiao C, Wu X, Yan P, Cui H, Yang C, Zhu J, Wu X, Tang M, Wang Y, Chen L, Liu Y, Zou Y, Zhang L, Yang C, Yao Y, Li J, Liu Z, Zhang B, Jiang X, International Headache Genetics Consortium. Migraine, chronic kidney disease and kidney function: observational and genetic analyses. Hum Genet 2023;142:1185-1200
doi: 10.1007/s00439-023-02575-9. Epub 2023 Jun 12.PMID: 37306871
Impact factor: 3.800
- Muñoz-Vendrell A, Campoy S, Caronna E, Alpuente A, Torres-Ferrus M, Nieves Castellanos C, Olivier M, Campdelacreu J, Prat J, Camiña Muñiz J, Molina Martinez FJ, Minguez-Olaondo A, Ruibal Salgado M, Santos Lasaosa S, Navarro Perez MP, Morollon N, Lopez Bravo A, Cano Sanchez LM, Garcia-Sanchez SM, Garcia-Ull J, Rubio-Flores L, Gonzalez-Martinez A, Quintas S, Echevarria Iñiguez A, Gil Luque S, Castro-Sanchez MV, Adell Ortega V, Garcia Alhama J, Berrocal-Izquierdo N, Belvis R, Diaz-Insa S, Pozo-Rosich P, Huerta Villanueva M. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients. Journal Headache Pain 2023;24:63
doi: 10.1186/s10194-023-01585-2.PMID: 37268904
Impact factor: 7.300
- Ashina M, Lanteri-Minet M, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B, Pozo-Rosich P. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study. Cephalalgia 2023;43: 3331024231170807
doi: 10.1177/03331024231170807.PMID: 37125484
Impact factor: 5.000
- Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (CA). Patterns of response to anti-CGRP monoclonal antibodies during the first 6-months of treatment in resistant migraine patients: impact on outcome. Eur J Neurol 2023;30:1937-1944
doi: 10.1111/ene.15816. Epub 2023 Apr 26.PMID: 37038303
Impact factor: 4.500
- Rovira-Simon J, Sales-i-Coll M, Pozo-Rosich P, Hueto-Madrid JA, Canovas Paradell R, Ochoa de Echagüen Aguilar A, Carbonell-Cobo M, de Castro R, Shaw G. The green surgical block 4.0: automation of the operating theatre’s climate conditions through a real-time patient-flow solution. Future Healthcare Journal 2023;10:1-4
Doi:10.7861/fhj.2022-0142. PMID 37786502
Impact factor: 1.200
- Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia 2023;3331024231159366
doi: 10.1177/03331024231159366.PMID: 36855951
Impact factor: 5.000
- Gallardo VJ, Gomez-Galvan JB, Asskour L, Torres-Ferrus M, Alpuente A, Caronna E, Pozo-Rosich P (CA). A study of differential microRNA expression profile in migraine: the microMIG exploratory study. Journal Headache Pain 2023;24(1):11
doi: 10.1186/s10194-023-01542-z.PMID: 36797674
Impact factor: 7.300
- Zhao L, Zhao W: International Headache Genetics Consortium; Cao J, Tu Y. Causal relationships between migraine and microstructural white matter: a Mendelian randomization study. Journal Headache Pain 2023;24(1):10
doi: 10.1186/s10194-023-01550-z.PMID: 36793015
Impact factor: 7.300
- Vila-Pueyo M, Cuenca-Leon E, Queiros AC, Kulis M, Sintas C, Cormand B, Martin-Subero JI, Pozo-Rosich P, Fernandez-Castillo N, Macaya A. Genome-wide DNA methylation analysis in an antimigraine-treated preclinical model of cortical spreading depolarization. Cephalalgia 2023;43: 3331024221146317.
doi: 10.1177/03331024221146317.PMID: 36759321
Impact factor: 5.000
- Gallardo VJ, Vila-Pueyo M, Pozo-Rosich P (CA). The impact of epigenetic mechanisms in migraine: Current knowledge and future directions. Cephalalgia 2023;43: 3331024221145916
doi: 10.1177/03331024221145916.PMID: 36759209
Impact factor: 5.000
- Welander NZ, Rukh G, Rask-Andersen M, Harder AVE, International Headache Genetics Consortium, van den Maagdenberg AMJM, Schiöth HB, Mwinyi J. Migraine, inflammatory bowel disease and celiac disease: a mendelian randomization study. Headache 2023;63::642-651.
doi: 10.1111/head.14470. PMID: 36705326
Impact factor: 5.400
- Caronna E, Pozo-Rosich P (CA). Virtual issue: COVID-19 and headache. Headache 2023;63:183-184
doi: 10.1111/head.14464. Epub 2023 Jan 12.PMID: 36633206
Impact factor: 5.400
- Caronna E, van den Hoek TC, Bolay H, Garcia-Azorin D, Gago-Veiga AB, Valeriani M, Takizawa T, Messlinger K, Shapiro RE, Goadsby PJ, Ashina M, Tassorelli C, Diener HC, Terwindt GM, Pozo-Rosich P (CA). Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: a comprehensive review. Cephalalgia 2023;43:3331024221131337.
doi: 10.1177/03331024221131337.PMID: 36606562
Impact factor: 5.000
- Lipton RB, Pozo-Rosich P, Blumenfeld A, Li Y, Severt L, Stokes JT, Creutz L, Gandhi P, Dodick D. Effect of atogepant for preventive migraine treatment on Patient-Reported Outcomes in the randomized, double-blind, phase 3 ADVANCE trial. Neurology 2022; Feb 21;100(8):e764-e777.
doi: 10.1212/WNL.0000000000201568. PMID: 36396451
Impact factor: 7.700
- Altamura C, Ornello R, Ahmed F, Nero A, Miscio AM, Santoro A, Alpuente A, Russo A, Silvestro M, Cevoli S, Brunelli N, Grazzi L, Baraldi C, Guerzoni S, Andreou AP, Lambru G, Frattale I, Kamm K, Ruscheweyh R, Russo M, Torelli P, Filatova E, Latysheva N, Gryglas-Dworak A, Straburzynski M, Butera C, Colombo B, Filippi M, Pozo-Rosich P, Martelletti P, Sacco S, Vernieri F. OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study. J Neurol 2022,270(2):986-994.
doi: 10.1007/s00415-022-11457-5. PMID: 36326890
Impact factor: 4.900
- Membrilla JA, Torres-Ferrus M, Alpuente A, Caronna E, Pozo-Rosich P (CA). Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: case series and narrative review. Headache 2022;62:1395-1405.
doi: 10.1111/head.14404. Epub 2022 Nov 2.PMID: 36321947
Impact factor: 5.000
- Pozo-Rosich P (CA), Dodick DW, Esttrup A, Hirman J, Cady R. Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc anaylsis of the PROMISE studies. BMC Neurology 2022;22:394.
doi: 10.1186/s12883-022-02914-9.PMID: 36284281
Impact factor: 2.600
- Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Uludüz S. Versijpt J, Ducros A, Gil-Gouveia R, Katsarava Z, Maetelletti P, Ornello R, Raffaelli B, Boucherie DM, Pozo-Rosich P, Sanchez-del-Rio M, Sinclair A, Maassen van den Brink A, Reuter U. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. Journal Headache Pain 2022;23:133
doi: 10.1186/s10194-022-01502-z.PMID: 36224519
Impact factor: 7.400
- Ornello R, Baraldi C, Ahmed F, Negro A, Miscio AM, Santoro A, Alpuente A, Russo A, Silvestro M, Cevoli S, Brunelli N, Vernieri F, Grazzi L, Pani L, Andreou A, Lambru G, Frattale I, Kamm K, Ruscheweyh R, Russo M, Torelli P, Filatova E, Latysheva N, Gryglas-Dworak A, Straburzynski M, Bultera C, Colombo B, Filippi M, Pozo-Rosich P, Martelletti P, Guerzoni S, Sacco S. Excellent response to onabotulinumtoxinA: different definitions, different predictors. Int J Environ Res Public Health 2022;19/17):10975
doi: 10.3390/ijerph191710975.PMID: 36078699
Impact factor: 4.614
- De Boer I, Ambrosini A, Halker Singh RB. Baykan B, Buse DC, Tassorelli C, Jensen RH, Pozo-Rosich P, Terwindt GM, International Headache Society Women’s Leadership Forum. Perceived barriers to career progression in the headache field: a global web-based cross-sectional survey. Cephalalgia 2022; 42(14):1498-1509.
doi: 10.1177/03331024221123081.PMID: 36071614
Impact factor: 4.900
- Gallardo VJ, Shapiro RE, Caronna E, Pozo-Rosich P (CA). The relationship of headache as a symptom to COVID-19 survival: a systematic review and meta-analysis of survival of 43,169 inpatients with COVID-19. Headache 2022; 62(8):1019-1028.
doi: 10.1111/head.14376. PMID: 36053077
Impact factor: 5.000
- Kristensen MGH, Do TP, Pozo-Rosich P, Amin FM. Interest in and exposure to headache disorders among neurology residents in Denmark: a nationwide cross-sectional survey. Acta Neurol Scand 2022; 146(5):568-572.
doi: 10.1111/ane.13681. PMID: 36004408
Impact factor: 3.500
- Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P (CA). Salivary CGRP and erenumab treatment response: towards precision medicine in migraine. Ann Neurol 2022;92:846-859
doi: 10.1002/ana.26472. PMID: 36054144
Impact factor: 11.200
- Gallardo VJ, Alpuente A, Pozo-Rosich P (CA). Association of a cyclical migraine phenotype with disease progression: a one-year time series analysis. Neurology 2022;99(12):e1326-e1334.
doi: 10.1212/WNL.0000000000200887. PMID: 35953289
Impact factor: 10.100
- Ikumi N, Cerda-Company X, Marti-Marca A, Vila-Ballo A, Caronna E, Gallardo VJ, Pozo-Rosich P (CA). Avoidance behaviour modulates but does not condition phonophobia in migraine. Cephalalgia 2022;42(13):1305-1316.
doi: 10.1177/03331024221111772. PMID: 35815637
Impact factor: 4.900
- Steiner TJ, Terwindt GM, Katsarava Z, Pozo-Rosich P, Gantenbein AR, Roche SL, Dell’Agnello G, Tassorelli C. Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process. Cephalalgia 2022;42:1287-1396
doi: 10.1177/03331024221110102. Epub 2022 Jul 5.PMID: 35791285
Impact factor: 4.900
- Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2022;21(7):597-607
doi: 10.1177/03331024221110102. Epub 2022 Jul 5.PMID: 35791285
Impact factor: 48.000
- Vilà-Balló A, Marti-Marca A, Torralba Cuello M, Soto-Faraco S, Pozo-Rosich P. The influence of temporal unpredictability on the electrophysiological mechanisms of neural entrainment. Psychophysiology 2022:e14108
doi: 10.1111/psyp.14108. PMID: 35678104
Impact factor: 3.700
- Mitchell BL, Diaz-Torres S, Bivol S, Cuella-Partida G; International Headache Genetics Consortium; Gerring ZF, Martin NG, Medland SE, Grasby KL, Nyholt DR, Renteria ME. Elucidating the relationship between migraine risk and brain structure using genetic data. Brain 2022;145:3214-3224
doi: 10.1016/S1474-4422(22)00185-5.PMID: 35716692
Impact factor: 14.500
- Lipton RB, Pozo-Rosich P, Blumenfeld AM, Dodick DW, McAllister P, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Rates of response to atogepant for migraine prophylaxis among adults: a secondary analysis of a randomized clinical trial. JAMA Netw Open 2022;5(6):e2215499
doi: 10.1001/jamanetworkopen.2022.15499.PMID: 35675076
Impact factor: 13.800
- Caronna E, Pozo-Rosich P (CA). Twenty twenty…two: Headache and COVID-19. Headache 2022; 62(6):648-649.
doi: 10.1111/head.14330. PMID: 35670131
Impact factor: 5.000
- Santos-Lasaosa S, Belvis R, Cuadrado ML, Diaz-Insa S, Gago-Veiga A, Guerrero-Peral AL, Huerta M, Irimia P, Lainez JM, Latorre G, Leira R, Pascual J, Porta-Etessam J, Sanchez del Rio M, Viguera J, Pozo-Rosich P. Calcitonin gene-related peptide in migraine: from pathophysiology to treatment. Neurologia 2022;37(5):390-402
doi: 10.1016/j.nrleng.2019.03.025. PMID: 35672126
Impact factor: 3.900
- Rovira-Simon J, Sales-i-Coll M, Pozo-Rosich P, Hueto-Madrid JA, Canovas Paradell R, Ochoa de Echagüen Aguilar A, Carbonell-Cobo M, de Castro R, Shaw G. Surgical block 4.0: a digital intervention based on a real-time location patient-flow solution to support the automation of surgical pathways. Future Healthcare Journal 2022;9:194-199
doi: 10.7861/fhj.2022-0005.PMID: 35928182
Impact factor: 0.900
- Schwedt TJ, Tassorelli C, Silberstein SD, Szperka CL, Kurth T, Pozo-Rosich P, Amin FM, Lipton RB, Dodick DW, Ashina M, Diener HC, Terwindt GM. Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1st Cephalalgia 2022 42(11-12):1099-1115.
doi: 10.1177/03331024221099035. PMID: 35514209
Impact factor: 4.900
- Mohamad Safiai NI, Mohamad NA, Basri H, Inche Mat LN, Hoo FK, Abdul Rasjid AM, Yusof Khan AHK, Loh WC, Baharin J, Fernandez A, Samsudin IN, Mohamed MH, Ching SM, Lee KW, Ramachandran V, Pozo-Rosich P, Wan Sulaiman WA. High-frequency repetitive trascranial magnetic stimulation at dorsolateral prefrontal cortex for migraine prevention: a systematic review and meta-analysis. Cephalalgia 2022;42:1071-1085.
doi: 10.1177/03331024221092423. Epub 2022 Apr 17.PMID: 35435045
Impact factor: 4.900
- Pozo-Rosich P, Detke HC, Wang S, Dolezil D, Li LQ. Aurora SK, Reuter U. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin 2022;38(5):731-742.
doi: 10.1080/03007995.2022.2059975. Epub 2022 Apr 15.PMID: 35392739
Impact factor: 2.300
- Pozo-Rosich P. Board Walk – April 2022. Cephalalgia 2022;42:427-429
doi: 10.1177/03331024211070712. PMID: 35383491
Impact factor: 4.900
- Rovira-Simon J, Sales-i-Coll M, Pozo-Rosich P, Gates D, Patt C, Hennessey I, Emery L, Hueto-Madrid JA, Carbonell-Cobo M, Garcia-Cuyas F, Moz M, Chaudry Z, Shaw G. Introduction to the cognitive hospital. Future Healthcare J 2022;9:34-40
doi: 10.7861/fhj.2021-0016.PMID: 35372780
Impact factor: 0.900
- Garcia-Azorin D, Layos-Romero A, Porta-Etessam J, Membrilla JA, Caronna E, Gonazalez-Martinez A, Mencia AS, Segura T, Gonzalez-Garcia N, Diaz de Teran J, Gallardo VJ, Gago-Veiga AB, Ballve A, Trigo-Lopez J, Sastre-Real A, Llaurado A, Cornejo A, de Lorenzo I, Guerrero-Peral A, Pozo-Rosich P. Post-COVID-19 persistent headache: a multicentric 9-months follow-up study of 905 patients. Cephalalgia 2022;42:804-809.
doi: 10.1177/03331024211068074. Epub 2022 Feb 15.PMID: 35166156
Impact factor: 4.900
- Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P (CA). In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. Journal Headache Pain 2021;22:151
doi: 10.1186/s10194-021-01366-9. PMID: 34903177
Impact factor: 8.588
- Caronna E, Pozo-Rosich P (CA). Headache as a symptom of COVID-19: narrative review of 1-year research. Current Pain and Headache Reports 2021;25:73
doi: 10.1007/s11916-021-00987-8. PMID: 34766205
Impact factor: 3.904
- Halker Singh RB, Bobker SM, Roberts JL, Charleston L 4th, Robbins MS, Pradhan A, Sprenger T, Pozo-Rosich P, Orr L, Powers SW, Houle TT, Turner DP, Gelfand AA. Advancing our commitment to our peer reviewers. Headache 2021;61(9):1299-1301.
doi: 10.1111/head.14211. Epub 2021 Oct 13.PMID: 34643953
Impact factor: 5.311
- Pozo-Rosich P (CA), Lucas C, Watson DPB, Gaul C, Ramsden E, Ritter S, Martelletti O, Snellman J. Burden of migraine in patients with preventive treatment failure attending European Headache Specialist Centers: Real-World Evidence from the BECOME study. Pain Ther 2021;10(2):1691-1708.
doi: 10.1007/s40122-021-00331-3. PMID: 34643891
Impact factor: 3.960
- Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. Journal Headache Pain 2021;22:120
doi: 10.1186/s10194-021-01328-1.PMID: 34620085
Impact factor: 8.588
- Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P (CA). Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks. Cephalalgia 2022;42:186-196
doi: 10.1177/03331024211040467. PMID: 34601944
Impact factor: 4.900
- Gallardo VJ, Alpuente A, Cerda-Company X, Torres-Ferrus M, Sanchez del Rio M, Lainez JM, Leira R, Trochet J, Pozo-Rosich P (CA). The impact of a digital platform on migraine patient-centered outcome research. Evaluation of midolordecabeza.org, a headache website in Spanish. Headache 2021;61:1403-1410.
doi: 10.1111/head.14225. Epub 2021 Oct 3.PMID: 34601726
Impact factor: 5.311
- Ornello R, Ahmed F, Negro A, Miscio AM, Santoro A, Alpuente A, Russo A, Silvestro M, Cevoli S, Brunelli N, Vernieri F, Grazzi L, Baraldi C, Guerzoni S, Andreou AP, Lambru G, Kamm K, Ruscheweyh R, Russo M, Torelli P, Filatova E, Latysheva N, Gryglas-Dworak A, Straburzynski M, Butera C, Colombo B, Filippi M, Pozo-Rosich P, Marterlletti P, Sacco S. Is there a gender difference in the response to onabotulinumtoxinA in chronic migraine? Insights from a Real-Life European Multicenter Study on 2879 patients. Pain Ther 2021; 10(2):1605-1618.
doi: 10.1007/s40122-021-00328-y. PMID: 34564833
Impact factor: 3.960
- Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). Toward a better understanding of persistent headache after mild COVID-19: Three migraine-like yet distinct scenarios. Headache 2021;10(2):1605-1618.
doi: 10.1007/s40122-021-00328-y. PMID: 34564833
Impact factor: 5.311
- Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). Epidemiology, work and economic impact of migraine in a large hospital cohort: time to raise awareness and promote sustainability. J Neurol 2022; 2022 Mar;269(3):1456-1462.
doi: 10.1007/s00415-021-10715-2. PMID: 34282471
Impact factor: 6.000
- Torres-Ferrus M, Pareto D, Gallardo VJ, Cuberas-Borros G, Alpuente A, Caronna E, Vila-Ballo A, Lorenzo-Bosquet C, Castell-Conesa J, Rovira A, Pozo-Rosich P (CA). Cortical metabolic and structural differences in patients with chronic migraine. An exploratory 18-FDG-PET and MRI study. Journal Headache Pain 2021;22(1):75
doi: 10.1186/s10194-021-01289-5.PMID: 34273945
Impact factor: 8.588
- Belvis R, Irimia P, Pozo-Rosich P, Gonzalez-Oria C, Cano A, Viguera J, Sanchez B, Beltran I, Oterino A, Cuadrado E, Gomez-Camello A, Alberte-Woodward M, Jurado C, Oms T, Ezpeleta D, de Teran JD, Morollon N, Latorre G, Torres-Ferrus M, Alpuente A, Lamas R, Toledano C, Leira R, Santos S, Sanchez del Rio MS. MAB-MIG: registry of the Spanish Neurological Society of erenumab for migraine prevention. Journal Headache Pain 2021;22(1):74
doi: 10.1186/s10194-021-01267-x. PMID: 34273947
Impact factor: 8.588
- Harder AVE, Winsvold BS, Noordam R, Vijhuizen LS, Borte S, Kogelman LJA, de Boer I, Tronvik E, Rosendaal FR, Willems van Dijk K, O’Connor E, Fourier C, Thomas LF, Kristoffersen ES; Cluster Headache Genetics Working Group, Fronczek R, Pozo-Rosich P, Jensen RH, Ferrari MD, Hansen TF, Zwart JA, Terwindt GM, van den Maagdenberg AMJM. Genetic susceptibility loci in genomewide association study of cluster headache. Ann Neurol 2021; 90(2):203-216.
doi: 10.1002/ana.26146. PMID: 34180076
Impact factor: 11.274
- Lainez JM, Ashina M, Belvis R, Diaz-Insa S, Ezpeleta D, Garcia-Azorin D, Gonzalez-Oria C, Guerrero AL, Guillem A, Holle-Lee D, Huerta-Vullanueva M, Irimia P, Leira R, Pascual J, Porta-Etessam J, Pozo-Rosich P, Rodriguez-Vico JS. Sanchez del Rio M, Santos-Lasaosa S, Silberstein S. 1st Post-European Headache Federation Meeting: a review of the latest developments presented at the 2020 European Headache Federation Congress. Rev Neurol 2021;72(s02):S1-S9
doi: 10.33588/rn.72s02.2021155.PMID: 34180043
Impact factor: 1.235
- Pozo-Rosich P (CA), Gil-Gouveia R, Donnet A, Poole AC, Gendolla A, Afridi S, Sanchez-de-la-Rosa R, Terwindt GM, Tassorelli C. Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My-LIFE European Delphi survey. Eur J Pain 2021;25(10):2177-2189
doi: 10.1002/ejp.1831. Epub 2021 Jul 13.PMID: 34173301
Impact factor: 3.651
- Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lanteri-Minet M, Braschinsky M, Sanchez del Rio M, Oved D, Özge A, Mammadbayli A, Arons M, Skorobogatykh, Romanenko V, Terwindt GM, Pamemeleire K, Sacco S, Reuter U, Lampl C, Schytz HW, Katsarava Z, Steiner TJ, Ashina M. Diagnosis and management of migraine in ten steps. Nat Rev Neurology 2021; 17(8):501-514.
doi: 10.1038/s41582-021-00509-5. PMID: 34145431
Impact factor: 44.711
- Mohamad Safiai NI, Mohamad NA, Basri H, Inche Mat LN, Hoo FK, Abdul Rashid AM, Yusof Khan AHK, Loh WC, Baharin J, Fernandez A, Samsudin IN, Mohamed MH, Siew MC, Lee KW, Ramachandran V, Pozo-Rosich P, Wan Sulaiman WA. High-frequency repetitive magnetic stimulation at dorsolateral prefrontal cortex for migraine prevention: a protocol for a systematic review of controlled trials. PLoS One 2021;16:e0251528
doi: 10.1371/journal.pone.0251528. eCollection 2021.PMID: 34138860
Impact factor: 3.752
- Gago-Veiga AB, Huhn JI, Latysheva N, Vieira Campos A, Torres-Ferrus M, Alpuente A, Sacco S, Frattale I, Ornello R, Ruscheweyh R, Marques IB, Gryglas-Dworak A, Stark C, Gallardo VJ, Pozo-Rosich P. InterMIG: international differences in the therapeutic approach to migraine patients in specialized headache centers. Journal Headache Pain 2021;22:43
doi: 10.1186/s10194-021-01258-y. PMID: 34030634
Impact factor: 8.588
- Sacco S, Lampl C, Maassen van den Brink A, Caponnetto V, Braschinsky M, Ducros A, Little P, Pozo-Rosich P, Reuter U, Sanchez del Rio M, Sinclair AJ, Martelletti P, Katsarava Z, Burden and Attitude to Resistant and Refractory (BARR) Study Group. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. Journal Headache Pain 2021, 22(1):39.
doi: 10.1186/s10194-021-01252-4. PMID: 34006218
Impact factor: 8.588
- Tassorelli C, Diener HC, Silberstein SD, Dodick DW, Goadsby PJ, Jensen RH, Magis D, Pozo-Rosich P, Yuan H, Martinelli D, Hoek TVD, Deen M, Ashina M, Terwindt GM. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for treatment of migraine. Cephalalgia 2021;41:1135-1151.
doi: 10.1177/03331024211010413. PMID: 33990161
Impact factor: 6.075
- Pazdera L, Cohen JM, Ning X, Campos VR, Yang R, Pozo-Rosich P. Fremanezumab for the preventive treatment of migraine: subgroup analysis by number of prior preventive treatments with inadequate response. Cephalalgia 2021 41(10):1075-1088.
doi: 10.1177/03331024211008401. PMID: 33990144
Impact factor: 6.075
- Irimia P, Garrido-Cumbrera M, Santos-Lasaosa S, Aguirre-Vazquez M, Correa-Fernandez J, Colomina I, Pozo-Rosich P. Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas. Sci Rep 2021;11:8286
doi: 10.1038/s41598-021-87352-2. PMID: 33859216
Impact factor: 4.997
- Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Sanchez-Mateo NM, Viguera-Romero J, Lopez-Veloso AC, Lopez-Bravo A, Gago-Veiga AB, Irimia P, Porta-Etessam J, Santos-Lasaosa S, Pozo-Rosich P (CA), Spanish CGRP-COVID Study Group. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications Neurologia 2021:36:611-7.
doi: 10.1016/j.nrl.2021.03.003. PMID: 33832802
Impact factor: 5.486
- Ornello R, Ahmed F, Negro A, Miscio AM, Santoro A, Alpuente A, Russo A, Silvestro M, Cevoli S, Brunelli N, Vernieri F, Grazzi L, Baraldi C, Guerzoni S, Andreou AP, lambru G, Frattale I, Kamm K, Ruscheweyh R, Russo M, Torelli P, Filatova E, Latysheva N, Gryglas-Dworak A, Straburzynski M, Butera C, Colombo B, Filippi M, Pozo-Rosich P, Martelletti P, Sacco S. Early management of onabotulinumotoxinA treatment in chronic migraine: insights from a real-life European multicenter study. Pain Ther 2021;10:637-650
doi: 10.1007/s40122-021-00253-0. Epub 2021 Mar 28.PMID: 33778933
Impact factor: 3.960
- Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, Krymchantowski AV, Lebedeva ER, Ravishankar K, Yu S, Sacco S, Ashina S, Younis A, Steiner TJ, Lipton RB. Migraine: epidemiology and systems of care. Lancet 2021;397(10283):1485-1495.
doi: 10.1016/S0140-6736(20)32160-7. PMID: 33773613
Impact factor: 202.731
- Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, Terwindt GM, Halker Singh R, Tassorelli C, Do TP, Mitsikostas DD, Dodick DW. Migraine: integrated approaches to clinical management and emerging treatments. Lancet 2021;397(10283):1505-1518.
doi: 10.1016/S0140-6736(20)32342-4. PMID: 33773612
Impact factor: 202.731
- Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (CA). The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 2021;268:3789-3798
doi: 10.1007/s00415-021-10523-8. PMID: 33772636
Impact factor: 6.682
- Ashina S, Mitsikostas DD, Lee MJ, Yamani N, Wang SJ, Messina R, Ashina H, Buse DC, Pozo-Rosich P, Jensen RH, Diener HC, Lipton RB. Tension-type headache. Nat Rev Dis Primers 2021;7:24
doi: 10.1038/s41572-021-00257-2. PMID: 33767185
Impact factor: 65.038
- Torres-Ferrus M, Lopez-Veloso AC, Gonzalez-Quintanilla V, Gonzalez-García N, Diaz de Teran J, Gago-Veiga A, Camiña J, Ruiz M, Mas-Sala N, Bohorquez S, Gallardo VJ, Pozo-Rosich P. The MIGREX study: prevalence and risk factors of sexual dysfunction among migraine patients. Neurologia 2021;S0213-4853.
doi: 10.1016/j.nrl.2021.02.006. PMID: 33766414
Impact factor: 5.486
- Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P (CA). Partial and non responders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal preventive treatment: a real-world evidence study. Eur J Neurol 2021;28(7):2378-2382.
doi: 10.1111/ene.14828. PMID: 33730441
Impact factor: 6.288
- Caronna E, Pozo-Rosich P (CA). Headache during COVID-19: lessons for all, implications for the International Classification of Headache Disorders. Headache 2021;61:385-386
doi: 10.1111/head.14059. PMID: 33522600
Impact factor: 5.311
- Diener HC, Ashina M, Durand-Zaleski I, Kurth T, Lanteri-Minet M, Lipton RB, Ollendorf DA, Pozo-Rosich P, Tassorelli C, Terwindt G. Health technology assessment for the acute and preventive treatment of migraine: a position statement of the International Headache Society. Cephalalgia 2021;28(7):2378-2382.
doi: 10.1111/ene.14828. PMID: 33730441
Impact factor: 6.075
- Vilà-Balló A, Martí-Marca A, Torres-Ferrus M, Alpuente A, Gallardo VJ, Pozo-Rosich P. Neurophysiological correlates of abnormal auditory processing in episodic migraine during the interictal period. Cephalalgia 2021;41:45-57
doi: 10.1177/0333102420951509. PMID: 32838536
Impact factor: 6.075
- Belvis R, Irimia P, Seijo-Fernandez F, Paz J, Garcia-March G, Santos-Lasaosa S, Latorre G, Gonzalez-Oria C, Rodríguez R, Pozo-Rosich P, Lainez JM. Neuromodulation in headache and craniofacial neuralgia: guidelines from the Spanish Society of Neurology and the Spanish Society of Neurosurgery. Neurologia 2021;36:61-79
doi: 10.1016/j.nrl.2020.04.022. PMID: 32718873
Impact factor: 5.486
- Pozo-Rosich P, Samman KH, Nicholson RA, Rettiganti M, Pearlman EM, Schwedt TJ. Galcanezumab provides consistent efficacy throughout the dosing interval among patients with episodic and chronic migraine: a post hoc analysis. Adv Therapy 2021;38:3154-3165
doi: 10.1007/s12325-021-01708-8. PMID: 33950375
Impact factor: 4.070
- Pozo-Rosich P (CA), Coppola G, Pascual J, Schwedt TJ. How does the brain change in chronic migraine? Developing disease biomarkers. Cephalalgia 2020;41(5):613-630.
doi: 10.1177/0333102420974359. Epub 2020 Dec 8. PMID: 33291995
Impact factor: 6.075
- Caronna E, Ballve A, Llaurado A, Gallardo VJ, Ariton DM, Lallana S, Lopez Maza S, Olive Gadea M, Quibus L, Restrepo JL, Rodrigo-Gisbert M, Vilaseca A, Hernandez Gonzalez M, Martinez Gallo M, Alpuente A, Torres-Ferrus M, Pujol Borrell R, Alvarez-Sabin J, Pozo-Rosich P (CA). Headache: a striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia 2020;40:1410-1421
doi: 10.1177/0333102420965157. PMID: 33146036
Impact factor: 6.295
- Pascual J, Pozo-Rosich P, Carrillo I, Rodriguez-Justo S, Jimenez-Hernandez D, Layos-Romero A, Bailon-Santamaría C, Torres A, Martinez-Garcia A, Ignacio E, Mira JJ. Proposal of a clinical care pathway for quality and safe management of headache patients: a consensus study report. BMJ Open 2020;10:e037190
doi: 10.1136/bmjopen-2020-037190. PMID: 33127628
Impact factor: 2.692
- Mulleners WM, Kim BK, Lainez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich MS, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC. Safety and efficacy of galcanezumab in patients whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicenter, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2020;19:814-825
doi: 10.1016/S1474-4422(20)30279-9. PMID: 32949542
Impact factor: 44.182
- Gonzalez-Oria C, Belvis R, Cuadrado ML, Diaz-Insa S, Guerrero-Peral AL, Huerta M, Irimia P, Lainez JM, Latorre G, Leira R, Oterino A, Pascual J, Porta-Etessam J, Pozo-Rosich P, Sanchez del Rio M, Santos-Lasaosa S. Document of revision and updating of medication overuse headache (MOH). Neurologia 2021;36:229-240.
doi: 10.1016/j.nrl.2020.04.029. PMID: 32917437
Impact factor: 5.486
- Pozo-Rosich P (CA), Martin-Delgado J, Layos-Romero A, Pascual J, Bailon C, Guerrero-Peral AL, Ignacio E, Torres A, Mira JJ. Specialised headache units, a feasible alternative in Spain. Rev Neurol 2020;71:199-204
doi: 10.33588/rn.7106.2020269. PMID: 32895902
Impact factor: 0.870
- Ruscheweyh R, Athwal B, Gryglas-Dworak A, Frattale I, Latysheva N, Ornello R, Pozo-Rosich P, Sacco S, Torres-Ferrus M, Stark CD. Wear-Off of OnabotulinumtoxinA effect over the treatment interval in chronic migraine: a retrospective chart review with analysis of headache diaries. Headache 2020;60:1673-1682
doi: 10.1111/head.13925. Epub 2020 Aug 14. PMID: 32797631
Impact factor: 5.887
- Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Houle TT, Hoek TCVD, Martinelli D, Terwindt GM; International Headache Society Clinical Trials Committee. Guidelines of the International Headache Society for Controlled Trials of Preventive Treatment of Migraine Attacks in Episodic Migraine in Adults. Cephalalgia 2020;40:1026-1044
doi: 10.1177/0333102420941839. Epub 2020 Jul 28.PMID: 32722936
Impact factor: 6.295
- Fonseca E, Torres-Ferrus M, Gallardo VJ, Macaya A, Pozo-Rosich P (CA). Impact of puberty in pediatric migraine: a pilot prospective study. J Clin Neurol 2020;16(3):416-422
doi: 10.3988/jcn.2020.16.3.416.PMID: 32657062
Impact factor: 3.077
- Torres-Ferrus M, Gallardo VJ, Alpuente A, Pozo-Rosich P (CA). Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. J Headache Pain 2020;21(1):88
doi: 10.1186/s10194-020-01157-8.PMID: 32652924
- Irimia P, Garrido-Cumbrera M, Santos-Lasaosa S, Braçe O, Colomina I, Blanch C, Pozo-Rosich P (CA). Estimating the savings of a migraine free life: results from the Spanish Atlas. Eur J Neurol 2020;27(12):2616-2624.
doi: 10.1111/ene.14431. Epub 2020 Aug 8. PMID: 32643853
Impact factor: 6.089
- Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM, Pozo-Rosich P, Reuter U, de la Torre ER, Del Rio MS, Sinclair AL, Katsarava Z, Martelletti P. European Headache Federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 2020;21:76
doi: 10.1186/s10194-020-01130-5.PMID: 32546227
Impact factor: 7.277
- Pozo-Rosich P (CA), Layos-Romero A, Martin-Delgado J, Pascual J, Bailon C, Tentor A, Santiago A, Ignacio E, Torres A, Mira JJ. Low-value care practice in headache: a Spanish mixed methods research study. J Headache Pain 2020;21:74
doi: 10.1186/s10194-020-01147-w. PMID: 32522142
Impact factor: 7.277
- Gonzalez-García N, Pozo-Rosich P. Comments on “Headache: Pregnancy and breastfeeding. Recommendations of the Spanish Society of Neurology’s Headache Study Group. Neurologia 2020;36(2):176.
doi: 10.1016/j.nrl.2020.01.005. Epub 2020 May 20.PMID: 32444176
Impact factor: 5.486
- Alpuente A, Gallardo VJ, Torres-Ferrus M, Santos-Lasaosa S, Guerrero A, Lainez JM, Viguera J, Gago-Veiga A, Irimia P, Del Rio MS, Pozo-Rosich P (CA). Evaluation of the concomitant use of oral preventive treatments and OnabotulinumtoxinA in chronic migraine: the PREVENBOX study. Eur J Neurol 2020;27:2102-2108
doi: 10.1111/ene.14331. PMID: 32421912
Impact factor: 6.089
- Bryois J, Skene NG, Folkmann Hansen T, Kogelman JA, Watson HJ, Liu Z, et al. Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson’s Disease. Nat Genet 2020; 52(5):482-493.
doi: 10.1038/s41588-020-0610-9. PMID: 32341526
Impact factor: 38.330
- Siewert KM, Klarin D, Damrauer SM, Chang KM, Taso PS, Assimes TL, Davey Smith G, Voight BF, the International Headache Genetics Consortium. Cross-trait analysis with migraine reveal widespread pleiotropy and suggest a vascular component to migraine headache. Int J Epidemiol 2020;49:1022-1031
doi: 10.1093/ije/dyaa050. PMID: 32306029
Impact factor: 7.196
- Alpuente A, Tassorelli C, Diener HC, Silberstein SD, Pozo-Rosich P (CA). Have the IHS Guidelines for controlled trials of acute treatment of migraine attacks been followed? Laying the ground for the 4th Cephalalgia 2020;40(8):778-787.
doi: 10.1177/0333102420906843. PMID: 32056459
Impact factor: 6.295
- Alpuente A, Gallardo VJ, Torres-Ferrus M, Alvarez-Sabin J, Pozo-Rosich P (CA). Short and mid-term predictors of response to onabotulinumtoxinA: real-life experience observational study. Headache 2020;60(4):677-685
doi: 10.1111/head.13765. PMID: 32086801
Impact factor: 5.887
- Caronna E, Gallardo VJ, Fonseca E, Gomez-Galvan JB, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA). How does migraine change after 10 years? A clinical cohort follow-up analysis. Headache 2020;60:916-928
doi: 10.1111/head.13774. PMID: 32068897
Impact factor: 5.887
- Kudrow D, Krege JH, Hundemer HP, Berg PH, Khanna R, Ossipov MH, Pozo-Rosich P. Issues impacting adverse event frequency and severity: differences between randomized phase 2 and phase 3 clinical trials for lasmiditan. Headache 2020;60:576-588
doi: 10.1111/head.13731. PMID: 31943195
Impact factor: 5.887
- Pozo-Rosich P (CA), Torres-Ferrus M. When does chronic migraine strike? Cephalalgia 2020;40:411-12
doi: 10.1177/0333102419885375. PMID: 31757168
Impact factor: 4.868
- Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 2019;394:1765-1774.
doi: 10.1016/S0140-6736(19)32504-8. PMID: 31668411
Impact factor: 60.390
- Diener HC, Goadsby PJ, Ashina M, Al-Karagholi MA, Sinclair A, Mitsikostas D, Magis D, Pozo-Rosich P, Sieira PI, Lainez MJ, Gaul C, Silver N, Hoffmann J, Marin J, Liebler E, Ferrari MD; PREMIUM Study Group. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicenter, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia 2019;39:1475-1487
doi: 10.1177/0333102419876920. PMID: 31522546
Impact factor: 4.868
- Santos-Lasaosa S, Belvis R, Cuadrado ML, Diaz-Insa S, Gago-Veiga A, Guerrero-Peral AL, Huerta M, Irimia P, Lainez JM, Latorre G, Leira R, Pascual J, Porta-Etessam J, Sanchez del Rio M, Viguera J, Pozo-Rosich P. Calcitonin gene-related peptide in migraine: from pathophysiology to treatment. Neurologia 2022;37(5):390-402.
doi: 10.1016/j.nrl.2019.03.013. Epub 2019 Jul 17. PMID: 31326215
Impact factor: 2.283
- Pozo-Rosich P, Martinez-García A, Pascual J, Ignacio E, Guerrero-Peral AL, Balseiro-Gomez J, Porta-Etessam J, Latorre-Gonzalez G, Layos-Romero A, Lucas C, Mira JJ. Quality assurance in specialized headache units in Spain: an observational prospective study. Journal Headache Pain 2019;20(1):73
doi: 10.1186/s10194-019-1020-1.PMID: 31238877
Impact factor: 4.797
- Alpuente A, Gallardo VJ, Torres-Ferrus M, Alvarez-Sabin J, Pozo-Rosich P (CA). Early efficacy and late gain in chronic and high frequency episodic migraine with onabotulinumtoxinA. Eur J Neurol 2019, 26:1464-1470
doi: 10.1111/ene.14028. PMID: 31220392
Impact factor: 4.516
- Gonzalez-Garcia N, Diaz de Teran J, Lopez-Veloso AC, Mas-Sala N, Minguez-Olaondo A, Ruiz-Piñero M, Gago-Veiga AB, Santos-Lasaosa S, Viguera-Romero J, Pozo-Rosich P. Headache: pregnancy and breastfeeding. Recommendations of the Spanish Society of Neurology’s Headache Study Group. Neurologia 2021. S2173-5808(21)00138-3
doi: 10.1016/j.nrl.2018.12.003. PMID: 31047730
Impact factor: 3.900
- Leira Y, Pozo-Rosich P, Torres-Ferrus M, Orlandi M, Lainez JM, Alvaro LC, Monzon MJ, Guerrero A, Garcia-Azorin D, Belvis R, Gonzalez-Oria C, Gago-Veiga AB, Latorre G, Santos S, Cuadrado ML, Blanco J, Leira R, D’Aiuto F. Self-reported periodontitis and migraine: results from a multi-center, cross-sectional survey in Spain. Odontology 2019; 107:530-535
doi: 10.1007/s10266-019-00430-w. PMID: 31030294
Impact factor: 1.840
- Abu-Arafeh I, Pozo-Rosich P. Board Walk – April 2019. Cephalalgia 2019;39:569-570
doi: 10.1177/0333102419834487.PMID: 30974968
- Torres-Ferrus M, Alpuente A, Pozo-Rosich P (CA). How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient’s perspective. Curr Opin Neurol 2019;32:395-404
doi: 10.1097/WCO.0000000000000689. PMID: 30950844
Impact factor: 4.207
- Bohorquez S, Pozo-Rosich P. Protocol for diagnosis and treatment of recent onset headache. Medicine 2019
- Gago-Veiga AB, Camiña Muñiz J, García-Azorín D, González-Quintanilla V, Ordás CM, Torres-Ferrus M, Santos-Lasaosa S, Viguera-Romero J, Pozo-Rosich P. Headache: What to ask, how to examine and which scales to use. Recommendations of the Spanish Society of Neurology’s Headache Study Group. Neurologia 2022 Sep;37(7):564-574.
doi: 10.1016/j.nrl.2018.12.006. PMID: 30929913
Impact factor: 2.283
- Reuter U, McClure C, Liebler E, Pozo-Rosich P. Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials. J Neurol Neurosurg Psychiatry 2019; 2019;90(7):796-804
doi: 10.1136/jnnp-2018-320113. PMID: 30824632
Impact factor: 8.263
- Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia 2019 May;39(6):687-710
doi: 10.1177/0333102419828967. PMID: 30806518
Impact factor: 4.868
- Carrillo I, Pozo-Rosich P, Guilabert M, Ignacio E, Pascual J, Porta-Etessam J, Guerrero-Peral AL, Mira JJ. Portfolio of services and basic table of quality indicators for Headache Units: a consensus study. Rev Neurol 2019;68:118-22.
PMID: 30687919
Impact factor: 0.652
- Caronna E, Gallardo VJ, Hernandez-Beltran N, Torres-Ferrus M, Pozo-Rosich P (CA). OnabotulinumtoxinA: an effective tool in the therapeutic arsenal for chronic migraine with medication overuse. Frontiers Neurology 2018;9:808
doi: 10.3389/fneur.2018.00808. PMID: 30386285
Impact factor: 2.635
- Bendtsen L, Sacco S, Ashina M, Mitsikostas M, Ahmed F, Pozo-Rosich P, Martelletti P. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain 2018;19:91
doi: 10.1186/s10194-018-0921-8. PMID: 30259200
Impact factor: 3.918
- Brainstorm Consortium. Analysis of shared heritability in common disorders of the brain. Science 2018;360(6395)
doi: 10.1126/science.aap8757. PMID: 29930110
Impact factor: 41.063
- Torres-Ferrus M, Vila-Sala M, Quintana M, Ajanovic S, Gallardo VJ, Gomez JB, Alvarez-Sabin J, Macaya A, Pozo-Rosich P (CA). Headache, comorbidities and lifestyle in an adolescent population (The TEENs Study). Cephalalgia 2019;39:91-99
doi: 10.1177/0333102418777509. PMID: 29771141
Impact factor: 4.868
- Yang Y, Zhao H, Boomsma DI, Ligthart L, Belin AC, Smith GD, Esko T, Freilinger TM, Hansen TF, Ikram MA, Kallela M, Kubisch C, Paraskevi C, Strachan DP, Wessman M; International Headache Genetics Consortium, van den Maagdenberg AMJM, Terwindt GM, Nyholt DR. Molecular genetic overlap between migraine and major depressive disorder. Eur J Hum Genet 2018;26:1202-1216
doi: 10.1038/s41431-018. PMID: 29995844
Impact factor: 3.650
- Gormley P, Kurki MI, Hiekkala ME, et al. Common variant burden contributes to the familial aggregation of migraine in 1589 families. Neuron 2018;98(4):743-753
doi: 10.1016/j.neuron.2018.04.014. PMID: 29731251
Impact factor: 14.403
- Dominguez C, Pozo-Rosich P, Leira Y, Leira R. Unilateral pain and shorter duration of chronic migraine are significant predictors of response to onabotulinumtoxinA. Eur J Neurol 2018;25:e48.
doi: 10.1111/ene.13570.PMID: 29575364
- Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 2018;38:815-832
doi: 10.1177/0333102418758283. PMID: 29504482
Impact factor: 4.438
- May A, Schwedt TJ, Magis D, Pozo-Rosich P, Evers S, Wang SJ. Cluster headache. Nat Rev Dis Primers 2018; 1;4:18006
doi: 10.1038/nrdp.2018.6.PMID: 29493566
Impact factor: 32.274
- Dominguez C, Pozo-Rosich P, Torres-Ferrus M, Hernandez-Beltran N. Jurado-Cobo C, Gonzalez-Oria C, Santos S, Monzon MJ, Latorre G, Alvaro LC, Gago A, Gallego A, Medrano V, Huerta M, Garcia-Alhama J, Belvis R, Leira Y, Leira R. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur J Neurol 2018;25:411-416
doi: 10.1111/ene.13523. PMID: 29171146
Impact factor: 4.387
- Santos Lasaosa ML, Cuadrado ML, Gago-Veiga AB, Guerrero Peral AL, Irimia P, Lainez JM, Leira R, Pascual J, Porta-Etessam J, Sanchez del Rio M, Viguera J, Pozo-Rosich P. Evidence and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine. Neurologia 2017; pii: S0213-4853(17)30319-5
doi: 10.1016/j.nrl.2017.09.003. PMID: 29169811
Impact factor: 2.283
- Gago-Veiga AB, Santos-Lasaosa S, Cuadrado ML, Guerrero AL, Irimia P, Lainez JM, Leira R, Pascual J, Sanchez del Rio M, Viguera J, Pozo-Rosich P. Evidence and experience with onabotulinumtoxinA in chronic migraine. Recommendations for daily clinical practice. Neurologia 2019 Jul-Aug;34(6):408-417.
doi: 10.1016/j.nrl.2017.09.008. PMID: 29169810
Impact factor: 2.283
- Gago-Veiga AB, García-Azorín D, Mas-Sala N, Ordás CM, Ruiz-Piñero M, Torres-Ferrus M, Santos Lasaosa S, Viguera Romero J, Pozo-Rosich P. How and when to refer patients diagnosed with primary headache and craniofacial neuralgia in the emergency department or primary care: recommendations of the Spanish Society of Neurology’s Study Group. Neurologia 2020 Apr;35(3):176-184.
doi: 10.1016/j.nrl.2017.08.001. PMID: 28870393
Impact factor: 3.109
- Gago-Veiga AB, Diaz de Terán J, Gonzalez-García N, Gonzalez-Oria C, Gonzalez-Quintanilla V, Minguez-Olaondo A, Santos-Lasaosa S, Viguera Romero J, Pozo-Rosich P. How and when to refer patients diagnosed with secondary headache and other craniofacial pain in the emergency department and primary care: recommendations of the Spanish Society of Neurology’s Headache Study Group. Neurologia 2020 Apr;35(3):176-184.
doi: 10.1016/j.nrl.2017.08.001. PMID: 28870393
Impact factor: 3.109
- Winsvold BS, Bettella F, Witoelar A, Anttila V, Gormley P, Kurth T, Terwindt GM, Freilinger TM, Frei O, Shadrin A, Wang Y, Dale AM, van den Maagdenberg AMJM, Chasman DI, Nyholt DR, Palotie A, Andreassen Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. J Headache Pain 2017;18:78.
doi: 10.1186/s10194-017-0784-4. PMID: 28766236
Impact factor: 3.403
- Ramos ML, García-Cabo C, Leira R, Domínguez C, Pozo-Rosich P, Vila C, Laínez MJ, Pascual J. Comorbidity between idiopathic overactive bladder and chronic migraine. Cephalalgia 2018 Mar;38(3):581-584.
doi: 10.1177/0333102417690127. PMID: 28114808
Impact factor: 4.438
- Winsvold BS, Bettella F, Witoelar A, Anttila V, Gormley P, Kurth T, Terwindt GM, Freilinger TM, Frei O, Shadrin A, Wang Y, Dale AM, van den Maagdenberg AMJM, Chasman DI, Nyholt DR, Palotie A, Andreassen OA, Zwart JA; International Headache Genetics Consortium. Shared genetic risk between migraine and coronary artery disease: A genome-wide analysis of common variants. PLoS One 2017;12:e0185663
doi: 10.137/journal.pone.0185663. PMID 28957430
Impact factor: 2.766
- Sintas C, Fernandez-Castillo N, Vila-Pueyo M, Pozo-Rosich P, Macaya A, Cormand B. Transcriptomic changes in rat cortex and brainstem after cortical spreading depression with or without pre-treatment with migraine prophylactic drugs. J Pain 2017;18(4):366-375.
doi: 10.1016/j.jpain.2016.11.007. PMID: 27919769
Impact factor: 4.859
- Aurora S, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Matharu M, Poster 411 The Impact of OnabotulinumtoxinA on Severe Headache Days: PREEMPT 24-Week pooled analysis. PM R 2016;8(9S):S296
doi: 10.1016/j.pmrj.2016.07.338. PMID: 27673163
Impact factor: 1.785
- Santos Lasaosa S, Gago Veiga A, Guerrero Peral AL, Viguera Romero J, Pozo-Rosich P. Patterns of anaesthetic pericranial nerve block in headache patients. Neurologia 2018 Apr;33(3):160-164.
doi: 10.1016/j.nrl.2016.05.016. PMID: 27461182
Impact factor: 2.038
- Santos Lasaosa S, Cuadrado Perez ML, Guerrero Peral AL, Huerta Villanueva M, Porta-Etessam J, Pozo-Rosich P, Pareja JA. Guía consenso sobre técnicas de infiltración anestésica de nervios pericraneales. Neurologia 2017 Jun;32(5):316-330.
doi: 10.1016/j.nrl.2016.04.017. PMID: 27342391
Impact factor: 1.938
- Gormley P, Anttila V, Winsvold BS, Palta P, Esko T, Pers TH, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet 2016;48:856-66.
doi: 10.1038/ng.3598. PMID: 27322543
Impact factor: 27.959
- Gago-Veiga AB, Santos-Lasaosa S, Viguera J. Pozo-Rosich P (CA). ¿Se interesan los residentes de neurología en cefaleas? Neurologia 2018 Jan-Feb;33(1):1-7.
doi: 10.1016/j.nrl.2016.04.013. PMID: 27328892
Impact factor: 2.038
- Torres-Ferrús M, Quintana M, Fernandez-Morales J, Alvarez-Sabin J, Pozo Rosich P (CA). When does chronic migraine strike? A clinical comparison according to the headache days suffered per month. Cephalalgia 2017;37:104-113
doi: 10.1177/0333102416636055. PMID: 26961321
Impact factor: 3.886
- Winsvold BS, Nelson CP, Malik R, Gormley P, Anttila V, Vander Heiden J, Elliott KS, Jacobsen LM, Palta P, Amin N, de Vries B, Hämäläinen E, Freilinger T, Ikram MA, Kessler T, Koiranen M, Ligthart L, McMahon G, Pedersen LM, Willenborg C, Won HH, Olesen J, Artto V, Assimes TL, Blankenberg S, Boomsma DI, Cherkas L, Davey Smith G, Epstein SE, Erdmann J, Ferrari MD, Göbel H, Hall AS, Jarvelin MR, Kallela M, Kaprio J, Kathiresan S, Lehtimäki T, McPherson R, März W, Nyholt DR, O’Donnell CJ, Quaye L, Rader DJ, Raitakari O, Roberts R, Schunkert H, Schürks M, Stewart AF, Terwindt GM, Thorsteinsdottir U, van den Maagdenberg AM, van Duijn C, Wessman M, KurthT, Kubisch C, Dichgans M, Chasman DI, Cotsapas C, Zwart JA, Samani NJ, Palotie A; CARDIoGRAM Consortium and the International Headache Genetics Consortium. Genetic analysis for a shared biological basis between migraine and coronary artery disease. Neurol Genet 2015 2;1:e10.
doi: 10.1212/NXG.0000000000000010
Impact factor: 3.509
- Zhao H, Eising E, de Vries B, Vijfhuizen LS; International Headache Genetics Consortium, Anttila V, Winsvold BS, KurthT, Stefansson H, Kallela M, Malik R, Stam AH, Ikram MA, Ligthart L, Freilinger T, Alexander M, Müller-Myhsok B, Schreiber S, Meitinger T, Aromas A, Eriksson JG, Boomsma DI, van Duijn CM, Zwart JA, Quaye L, Kubisch C, Dichgans M, Wessman M, Stefansson K, Chasman DI, Palotie A, Martin NG, Montgomery GW, Ferrari MD, Terwindt GM, van den Maagdenberg AM, Nyholt DR. Gene-based pleiotropy across migraine with aura and migraine without aura patient groups. Cephalalgia 2016;36:648-57
Impact factor: 3.609
- Torres-Ferrús M, Pozo-Rosich P (CA). Posicionamiento de las unidades de cefalea en el ámbito de la neurología: la importancia de la toxina botulínica y otras terapias en el tratamiento de la cefalea. Rev Neurol 2015;61(Suppl 1:S3-7)
PMID: 26337644
Impact factor: 1.79
- Pozo-Rosich P (CA). Unidades de cefalea en el ámbito de la neurología. Rev Neurol 2015;61(Suppl 1):S1-2.
PMID: 26337641
Impact factor: 1.79
- Pozo-Rosich P (CA), Storer RJ, Charbit A, Goadsby PJ. Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. Cephalalgia 2015,35(14):1298-307.
doi: 10.1177/0333102415576723. PMID: 25792688
Impact factor: 6.052
- Sintas C, Fernandez-Morales J, Vila-Pueyo M, Narberhaus B, Arenas C, Pozo-Rosich P, Macaya A, Cormand B. Replication study of previous migraine genome-wide association study findings in a Spanish sample of migraine with aura. Cephalalgia 2015;35(9):776-82.
doi: 10.1177/033310241455784. PMID: 25388962
Impact factor: 6.052
- Nyholt DR; International Headache Genetics Consortium, Anttila V, Winsvold BS, KurthT, Stefansson H, Kallela M, Malik R, Vries Bd, Terwindt GM, Ikram MA, Stam AH, Ligthart L, Freilinger T, Alexander M, Muller-Myhsok B, Schreiber S, Meitinger T, Aromaa A, Eriksson JG, Kaprio J, Boomsma DI, Duijn Cv, Raitakari O, Järvelin MR, Zwart JA, Quaye L, Strachan DP, Kubisch C, Ferrari MD, van den Maagdenberg AM, Dichgans M, Wessman M, Smith GD, Stefansson K, Chasman DI, Palotie A. Concordance of genetic risk across migraine subgroups: impact on current and future genetic association studies. Cephalalgia 2015;35:489-99
- Chasman DI, Anttila V, Buring JE, Ridker PM, Schürks M, KurthT; International Headache Genetics Consortium. Selectivity in genetic association with sub-classified migraine in women. PLoS Genet 2014;10:e1004366
- Sanchez del Rio M, Leira R, Pozo-Rosich P, Lainez JM, Alvarez R, Pascual J. Errors in recognition and management are still frequent in patients with cluster headache. European Neurology 2014;72:209-212.
doi: 10.1159/000362517. PMID: 25227490
Impact factor (2013) 1.362
- Louter M, Fernandez-Morales J, de Vries B, Winsvold B, Anttila V, Fernandez-Cadenas I, Vila-Pueyo M, Sintas C, van Duijn C, Cormand B, Alvarez-Sabin J, Montaner J, Ferrari M, van den Maagdenberg A, Palotie A, Zwart J, Macaya A, Terwindt G, Pozo-Rosich P (CA). Candidate-gene association study searching for genetic factors involved in migraine chronification. Cephalalgia 2015;35:500-7.
doi: 10.1177/0333102414547141. PMID: 25169732
Impact factor (2013) 4.121. Clinical Neurology 32 out of 194/ Neurosciences 71 out of 251.
- Gomez-Mancilla B, Brand R, Jürgens TP, Göbel H, Sommer C, Evers S, Sommer M, Campos V, Kalkman HO, Hariry S, Pezous N, Johns D, Diener HC, BGG492 Study Group. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia 2014;34:103-13.
- Pozo-Rosich P (CA). What benefits does the preventive treatment of migraine have? Rev Neurol 2014;58 Suppl 2:S21-6.
PMID: 24687881
Impact factor (2013) 0.926
- Pozo-Rosich P (CA). Importance of diagnosis and treatment in chronic migraine. Rev Neurol 2014;58. Suppl 2:S1.
PMID: 24687879
Impact factor (2013) 0.926.
- Pozo-Rosich P (CA). Chronic migraine: its epidemiology and impact. Rev Neurol 2012;54. Suppl 2:S3-11.
PMID: 22532240
Impact factor (2011) 1,083.
- Sintas C, Carreño O, Fernandez-Morales J, Cacheiro P, Sobrido MJ, Naberhaus B, Pozo-Rosich P, Macaya A, Cormand B. A replication study of a GWAS finding in migraine does not identify association in a Spanish case-control sample. Cephalalgia 2012;32:1076-80.
doi: 10.1177/0333102412457090. PMID: 22908361
Impact factor (2011) 3,430. Ranking: 44/191 (Clinical Neurology), 89/243 (Neurosciences)
- Freilinger T, Anttila V, de Vries B, Malik R, Kallela M, Terwindt G, Pozo-Rosich P, et al. For the International Headache Genetics Consortium. Genome-wide association analysis identifies several susceptibility loci for migraine without aura. Nature Genetics 2012;44:777-782.
doi: 10.1038/ng.2307. PMID: 22683712
Impact factor (2011) 35,532. Ranking 1/156 in genetics.
- Färkkilä M, Diener HC, Géraud G, Láinez M, Schoenen J, Harner N, Pilgrim A, Reuter U, & COL MIG-202 study group. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised placeo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11:405-13.
doi: 10.1016/S1474-4422(12)70047-9. PMID: 22459549
Impact factor: 23.917
- Poca MA, Galard R, Serrano E, Merino MA, Pozo-Rosich P, Solana E, Mestres O, de la Calzada MD, Sahuquillo J. Normal hypocretin-1 (orexin A) levels in cerebrospinal fliud in patients with idiopathic intracranial hypertension. Acta Neurochir Suppl. 2012;114:221-5.
doi: 10.1007/978-3-7091-0956-4_43. PMID: 22327697
Impact factor 1,329.
- Carreño O, Corominas R, Fernandez-Morales J, Camiña M, Sobrido MJ, Fernandez-Fernandez JM, Pozo-Rosich P, Cormand B, Macaya A. SNP variants within the vanilloid TRPV1 and TRPV3 receptor genes are associated with migraine in the Spanish population. Am J Med Genet B Neuropsychiatr Genet 2012;159B(1):94-103.
doi: 10.1002/ajmg.b.32007. PMID: 22162417
Impact factor (2011): 3,430. Ranking WoS: 42/157 (Genetics & Hereditary), 30/129 (Psychiatry).
- Pascual J, Sanchez del Río M, Jimenez MD, Lainez-Andres JM, Mateos V, Leira R, Pozo-Rosich P, Guzman-Quilo C. La migraña crónica vista por el neurólogo y el paciente: resultados del proyecto CIEN-mig (III). Rev Neurol 2010;50:705-710.
PMID: 20533248
Impact factor 1,234
- Pascual J, Sanchez del Río M, Jimenez MD, Lainez-Andres JM, Mateos V, Leira R, Pozo-Rosich P, Guzman-Quilo C. Satisfacción del paciente con migraña que acude a consultas de neurología: resultados del proyecto CIEN-mig (II). Rev Neurol 2010;50:641-645.
PMID: 20514635
Impact factor 1,234
- Pascual J, Sanchez del Río M, Jimenez MD, Lainez-Andres JM, Mateos V, Leira R, Pozo-Rosich P, Guzman-Quilo C. Actitud del neurólogo español frente a la migraña: resultados del proyecto CIEN-mig (I). Rev Neurol 2010;50:577-583.
PMID: 20473832
Impact factor 1,234
- Río-Espinola A, Mendióroz M, Domingues-Montanari S, Pozo-Rosich P, Solé E, Fernández-Morales J, Fernández-Cadenas I, Montaner J. CADASIL management or what to do when there is little one can do. Expert Rev Neurother 2009;9:197-210.
doi: 10.1586/14737175.9.2.197. PMID: 19210195
Impact factor 2,991.
- Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Dalmau J. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 2005; 165:166-71.
doi: 10.1016/j.jneuroim.2005.03.020. PMID: 15949849
Impact factor 2,92.
- Siow C, Pozo-Rosich P, Silberstein SD. Frovatriptan for the treatment of cluster headache. Cephalalgia 2004;24:1045-8.
doi: 10.1111/j.1468-2982.2004.00734.x. PMID: 15566418
Impact factor 3,775.
- Pozo-Rosich P, Clover L, Saiz A, Vincent A, Graus F. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 2003;54:530-3.
doi: 10.1002/ana.10713. PMID: 14520669
Impact factor 8,813.
- Villoslada P, Juste C, Tintore M, Llorens V, Codina G, Pozo-Rosich P, Montalban X. The immune response against herpesvirus is more prominent in the early stages of MS. Neurology 2003;60:1944-1948.
doi: 10.1212/01.wnl.0000069461.53733.f7. PMID: 12821737
Impact factor 6,014.
- Young WB, Pozo-Rosich P, Paolone MF. Alternative Therapies for Headache. Curr Treat Options Neurol 2003;5:441-553.
doi: 10.1007/s11940-996-0013-y. PMID: 14516522
Impact factor 1,556. - Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology. 2002; 59:764-6.
doi: 10.1212/wnl.59.5.764.PMID: 12221175.
Impact factor 6,014.
- Pozo-Rosich P, Villoslada P, Canton A, Simo R, Rovira A, Montalban X. Reversible white matter alterations in encephalopathy associated with autoimmune thyroid disease. J Neurol 2002; 249:1063-5.
doi: 10.1007/s00415-002-0788-z.PMID: 12195455. Impact factor 2,477.